Valuation: UCB

Market Cap 38.51B 43.15B 35.8B 32.56B 61.26B 4,087B 62.36B 430B 168B 2,132B 162B 158B 6,823B P/E 2026 *
20.2x
P/E 2027 * 16.8x
Enterprise Value 38.93B 43.61B 36.18B 32.91B 61.91B 4,131B 63.03B 435B 170B 2,155B 164B 160B 6,896B EV / Sales 2026 *
4.5x
EV / Sales 2027 * 3.83x
Free-Float
61.59%
Yield 2026 *
0.72%
Yield 2027 * 0.74%
1 day+1.98%
1 week+2.08%
Current month+0.44%
1 month-1.86%
3 months-12.60%
6 months-22.47%
Current year-13.66%
1 week 197.45
Extreme 197.45
208
1 month 197.45
Extreme 197.45
217.1
Current year 197.45
Extreme 197.45
289.5
1 year 197.45
Extreme 197.45
289.5
3 years 65.4
Extreme 65.4
289.5
5 years 65.4
Extreme 65.4
289.5
10 years 54.84
Extreme 54.84
289.5
Manager TitleAgeSince
Chief Executive Officer 67 31/12/2014
Director of Finance/CFO 60 30/06/2020
Chief Tech/Sci/R&D Officer 59 30/04/2024
Director TitleAgeSince
Director/Board Member 55 31/12/2011
Director/Board Member 67 31/12/2014
Director/Board Member 56 23/04/2014
Date Insider Type Main position Quantity % Market Cap. Importance
15/01/26 Exercice

Executive/Senior Manager

3,000 0.0015%
15/01/26 Exercice

Executive/Senior Manager

3,000 0.0015%
15/01/26 Buy

Director

500 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+1.98%+2.08%-19.75%+157.24% 42.84B
+4.82%+8.43%+53.43%+105.67% 1,077B
-0.31%-1.22%+32.53%+60.83% 612B
+1.21%+4.50%+25.85%+93.36% 501B
-0.40%+3.35%+74.94%+41.30% 364B
+2.37%+7.66%+33.65%+50.58% 353B
+2.64%+6.95%+21.01%+44.38% 278B
+3.24%+6.78%+0.43%+15.73% 251B
+3.02%+7.89%+47.85%+53.23% 230B
+3.29%+7.86%+34.12%+100.33% 190B
Average +2.12%+1.68%+30.41%+72.27% 389.94B
Weighted average by Cap. +2.32%+1.56%+39.03%+73.11%

Financials

2026 *2027 *
Net sales 8.66B 9.7B 8.05B 7.32B 13.77B 919B 14.02B 96.67B 37.82B 479B 36.4B 35.63B 1,534B 9.61B 10.76B 8.93B 8.12B 15.28B 1,019B 15.55B 107B 41.96B 532B 40.39B 39.53B 1,702B
Net income 1.93B 2.16B 1.79B 1.63B 3.07B 205B 3.12B 21.52B 8.42B 107B 8.11B 7.93B 342B 2.3B 2.57B 2.13B 1.94B 3.65B 244B 3.72B 25.64B 10.03B 127B 9.66B 9.45B 407B
Net Debt 413M 462M 384M 349M 656M 43.79B 668M 4.61B 1.8B 22.85B 1.73B 1.7B 73.11B -1.7B -1.9B -1.58B -1.43B -2.7B -180B -2.74B -18.92B -7.4B -93.84B -7.13B -6.98B -300B
Projected Income Statement - Annual - UCB
Logo UCB
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Employees
9,000
Date Price Change Volume
15/10/26 €206.00 +1.98% 399,204
14/10/26 €202.00 +2.07% 400,807
13/10/26 €197.90 -2.94% 205,064
12/10/26 €203.90 +0.20% 140,585
09/10/26 €203.50 +0.84% 207,342
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - UCB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
202.00EUR
Average target price
285.00EUR
Spread / Average Target
+41.09%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - UCB